These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 35734348)

  • 1. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer.
    Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J
    Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.
    Bai Y; Xie T; Wang Z; Tong S; Zhao X; Zhao F; Cai J; Wei X; Peng Z; Shen L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35241494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.
    Chen X; Zhang H; Wang M; Liu H; Hu Y; Lin T; Chen H; Zhao M; Chen T; Li G; Yu J; Zhao L
    Front Immunol; 2022; 13():783695. PubMed ID: 35401534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological characteristics and prognosis of Epstein-Barr virus-associated gastric cancer.
    Li LL; Yu AY; Zhu M; Ma LY; Cao MH; Liu WL; Qin XB; Gao C; Han ZX; Wang HM
    Arch Virol; 2024 May; 169(5):114. PubMed ID: 38700535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical impact of testing for biomarkers in gastric cancer patients: a real-world cohort.
    van der Sluis K; van Sandick JW; van Dieren JM; Vollebergh MA; Grootscholten C; van den Berg JG; Snaebjornsson P; Hartemink KJ; Veenhof AAFA; Chalabi M; Kodach LL
    Histopathology; 2023 May; 82(6):826-836. PubMed ID: 36694277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
    Akimoto E; Kuwata T; Shitara K; Kawazoe A; Sakamoto N; Ishii G; Ochiai A; Kinoshita T
    Ann Surg Oncol; 2023 Aug; 30(8):5227-5236. PubMed ID: 36934377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
    Zhang L; Wang Y; Li Z; Lin D; Liu Y; Zhou L; Wang D; Wu A; Li Z
    Diagn Pathol; 2021 May; 16(1):38. PubMed ID: 33933102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
    Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
    J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Hewitt LC; Inam IZ; Saito Y; Yoshikawa T; Quaas A; Hoelscher A; Bollschweiler E; Fazzi GE; Melotte V; Langley RE; Nankivell M; Cunningham D; Allum W; Hutchins GG; Grabsch HI
    Eur J Cancer; 2018 May; 94():104-114. PubMed ID: 29550565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
    Pereira MA; Ramos MFKP; Faraj SF; Dias AR; Yagi OK; Zilberstein B; Cecconello I; Alves VAF; de Mello ES; Ribeiro U
    J Surg Oncol; 2018 Apr; 117(5):829-839. PubMed ID: 29534305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
    Kawazoe A; Shitara K; Kuboki Y; Bando H; Kojima T; Yoshino T; Ohtsu A; Ochiai A; Togashi Y; Nishikawa H; Doi T; Kuwata T
    Gastric Cancer; 2019 Jan; 22(1):69-76. PubMed ID: 29859006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
    Gullo I; Oliveira P; Athelogou M; Gonçalves G; Pinto ML; Carvalho J; Valente A; Pinheiro H; Andrade S; Almeida GM; Huss R; Das K; Tan P; Machado JC; Oliveira C; Carneiro F
    Gastric Cancer; 2019 Jan; 22(1):77-90. PubMed ID: 29779068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients].
    Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinicopathological and immune characterization of mismatch repair deficient endocervical adenocarcinoma.
    Wu YW; Wei LJ; Yang X; Liang HY; Cai MY; Luo RZ; Liu LL
    Oncologist; 2024 Oct; 29(10):e1302-e1314. PubMed ID: 39110901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.